These are top 10 stocks traded on the Robinhood UK platform in July
On Thursday, Canaccord Genuity adjusted its price target for The Beauty Health Company (NASDAQ:SKIN) shares, reducing it to $1.50 from the previous $1.75, while maintaining a Hold rating on the stock. According to InvestingPro data, the company’s market capitalization stands at $176 million, with the stock trading significantly below its 52-week high of $5.17. The decision came after the company reported its fourth-quarter sales, which saw a decline of 13.8% to $83.5 million. This figure, however, was better than both Canaccord’s and the Street’s expectations, which anticipated a 20.4% and 20.3% decline respectively.
The Beauty Health Company’s adjusted EBITDA was $9.0 million, surpassing the estimates, which predicted a loss. The company’s performance exceeded its own guidance, which ranged from a loss of $5 million to a gain of $1 million. InvestingPro analysis shows the company maintains a strong liquidity position with a current ratio of 6.56, though profitability remains challenged with negative returns on assets and equity. Despite the downturn in sales, the company’s high-margin consumables business continued to perform strongly, maintaining a gross profit margin of 50.5%.
The company’s new machine placements are currently facing significant challenges due to the broader macroeconomic conditions. In response to these pressures, management has taken steps to manage costs, including transitioning its China business from a direct sales model to a distributor model. Additionally, they are trying to boost machine uptake by offering lower-cost and refurbished machines at more competitive price points than their premium Syndeo machines. InvestingPro has identified several key factors affecting the company’s performance, including potential interest payment challenges and aggressive share buybacks by management. Subscribers can access 9 additional ProTips and comprehensive financial analysis in the Pro Research Report.
Nevertheless, these efforts have not been sufficient to counteract the negative impact of the worsening macro conditions and the high-interest rate environment. Consequently, the management has set the fiscal year 2025 sales guidance lower than that of fiscal year 2024, mainly due to the expectation of continued lower machine placements.
Canaccord Genuity’s analyst commented on the situation, stating that they will remain on the sidelines until there is a stabilization in system sales. The revised price target reflects the ongoing challenges faced by The Beauty Health Company in the current economic climate.
In other recent news, Beauty Health Co has reported its fourth-quarter earnings for 2024, surpassing analyst expectations. The company achieved an earnings per share (EPS) of -$0.08, outperforming the forecasted -$0.11, with revenue reaching $83.5 million, exceeding the expected $77.39 million. For the full year, Beauty Health Co’s revenue totaled $334 million, surpassing its guidance. Despite the positive earnings report, the company’s stock experienced a decline in aftermarket trading. In addition to financial results, Beauty Health Co also managed to reduce its operating expenses by over $30 million and ended the quarter with a strong cash position of $370 million.
Looking ahead, Beauty Health Co projects 2025 sales between $270 million and $300 million, with adjusted EBITDA expected to range from $10 million to $25 million. The company plans to focus on consumable sales and provider utilization as part of its strategic initiatives. In terms of market strategy, Beauty Health Co is transitioning to a third-party distributor model in China, which is expected to impact sales but aims to improve long-term profitability. This strategic shift is part of the company’s broader efforts to optimize its international footprint while maintaining financial discipline.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.